116 related articles for article (PubMed ID: 38921803)
1. The Effect of Exposure to SARS-CoV-2 Vaccination and Infection on Humoral and Cellular Immunity in a Cohort of Patients with Immune-Mediated Diseases: A Pilot Study.
Costanzo GAML; Sanna G; Pes F; Deiana CM; Ledda AG; Perra A; Palmas V; Manca V; Miglianti M; Coghe F; Manzin A; Del Giacco S; Chessa L; Firinu D
Pathogens; 2024 Jun; 13(6):. PubMed ID: 38921803
[TBL] [Abstract][Full Text] [Related]
2. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of humoral and cellular response to third dose of BNT162b2 mRNA COVID-19 vaccine in patients treated with B-cell depleting therapy.
Firinu D; Fenu G; Sanna G; Costanzo GA; Perra A; Campagna M; Littera R; Locci C; Marongiu A; Cappai R; Melis M; Orrù G; Del Giacco S; Coghe F; Manzin A; Chessa L
J Autoimmun; 2022 Jul; 131():102848. PubMed ID: 35714496
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease.
Haberman RH; Herati RS; Simon D; Samanovic M; Blank RB; Tuen M; Koralov SB; Atreya R; Tascilar K; Allen JR; Castillo R; Cornelius AR; Rackoff P; Solomon G; Adhikari S; Azar N; Rosenthal P; Izmirly P; Samuels J; Golden B; Reddy S; Neurath M; Abramson SB; Schett G; Mulligan MJ; Scher JU
medRxiv; 2021 May; ():. PubMed ID: 34013285
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination.
Firinu D; Perra A; Campagna M; Littera R; Fenu G; Meloni F; Cipri S; Sedda F; Conti M; Miglianti M; Costanzo G; Secci M; Usai G; Carta MG; Cappai R; Orrù G; Del Giacco S; Coghe F; Chessa L
Clin Exp Med; 2022 Aug; 22(3):477-485. PubMed ID: 34741188
[TBL] [Abstract][Full Text] [Related]
6. Impact of Exposure to Vaccination and Infection on Cellular and Antibody Response to SARS-CoV-2 in CVID Patients Through COVID-19 Pandemic.
Costanzo GAML; Deiana CM; Sanna G; Perra A; Campagna M; Ledda AG; Coghe F; Palmas V; Cappai R; Manzin A; Chessa L; Del Giacco S; Firinu D
J Clin Immunol; 2023 Dec; 44(1):12. PubMed ID: 38129351
[TBL] [Abstract][Full Text] [Related]
7. Humoral and cellular immune responses in fully vaccinated individuals with or without SARS-CoV-2 breakthrough infection: Results from the CoV-ADAPT cohort.
Hollstein MM; Dierks S; Schön MP; Bergmann A; Abratis A; Eidizadeh A; Kaltenbach S; Schanz J; Groß U; Leha A; Kröger A; Andag R; Zautner AE; Fischer A; Erpenbeck L; Schnelle M
J Med Virol; 2023 Oct; 95(10):e29122. PubMed ID: 37787583
[TBL] [Abstract][Full Text] [Related]
8. Humoral and cellular response of two different vaccines against SARS-CoV-2 in a group of healthcare workers: An observational study.
Stambouli N; Bahrini K; Romdhani C; Rebai A; Boughariou S; Zakraoui M; Arfaoui B; Seyli S; Boukhalfa Y; Battikh R; Moussa MB; Labbene I; Ferjani M; Gharssallah H
J Immunol Methods; 2024 May; 528():113665. PubMed ID: 38490578
[TBL] [Abstract][Full Text] [Related]
9. Humoral and cellular responses to spike of δ SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases.
Petrone L; Picchianti-Diamanti A; Sebastiani GD; Aiello A; Laganà B; Cuzzi G; Vanini V; Gualano G; Grifoni A; Ferraioli M; Castilletti C; Meschi S; Vaia F; Nicastri E; Sette A; Goletti D
Int J Infect Dis; 2022 Aug; 121():24-30. PubMed ID: 35462039
[TBL] [Abstract][Full Text] [Related]
10. Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARS-CoV-2 in Adult Patients with Immune-Mediated Inflammatory Diseases.
Cheung MW; Dayam RM; Shapiro JR; Law JC; Chao GYC; Pereira D; Goetgebuer RL; Croitoru D; Stempak JM; Acheampong L; Rizwan S; Lee JD; Jacob L; Ganatra D; Law R; Rodriguez-Castellanos VE; Kern-Smith M; Delgado-Brand M; Mailhot G; Haroon N; Inman RD; Piguet V; Chandran V; Silverberg MS; Watts TH; Gingras AC
J Immunol; 2023 Aug; 211(3):351-364. PubMed ID: 37326480
[TBL] [Abstract][Full Text] [Related]
11. Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity.
van Dam KPJ; Volkers AG; Wieske L; Stalman EW; Kummer LYL; van Kempen ZLE; Killestein J; Tas SW; Boekel L; Wolbink GJ; van der Kooi AJ; Raaphorst J; Takkenberg RB; D'Haens GRAM; Spuls PI; Bekkenk MW; Musters AH; Post NF; Bosma AL; Hilhorst ML; Vegting Y; Bemelman FJ; Voskuyl AE; Broens B; Sanchez AP; van Els CACM; de Wit J; Rutgers A; de Leeuw K; Horváth B; Verschuuren JJGM; Ruiter AM; van Ouwerkerk L; van der Woude D; Allaart RCF; Teng YKO; van Paassen P; Busch MH; Jallah PBP; Brusse E; van Doorn PA; Baars AE; Hijnen DJ; Schreurs CRG; van der Pol WL; Goedee HS; Steenhuis M; Keijzer S; Keijser JBD; Cristianawati O; Ten Brinke A; Verstegen NJM; van Ham SM; Rispens T; Kuijpers TW; Löwenberg M; Eftimov F;
BMC Infect Dis; 2023 May; 23(1):332. PubMed ID: 37198536
[TBL] [Abstract][Full Text] [Related]
12. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
[TBL] [Abstract][Full Text] [Related]
13. [Investigation of SARS-CoV-2-Specific Humoral and Cellular Immunity Values in Health Care Workers with COVID-19 Disease and Administered with COVID-19 Vaccine].
Keskin AÜ; Dalan AB; Çıragil P; Topkaya AE
Mikrobiyol Bul; 2022 Jul; 56(3):480-492. PubMed ID: 35960239
[TBL] [Abstract][Full Text] [Related]
14. Impaired Humoral Immunity with Concomitant Preserved T Cell Reactivity in IBD Patients on Treatment with Infliximab 6 Month after Vaccination with the SARS-CoV-2 mRNA Vaccine BNT162b2: A Pilot Study.
Vollenberg R; Tepasse PR; Lorentzen E; Nowacki TM
J Pers Med; 2022 Apr; 12(5):. PubMed ID: 35629116
[TBL] [Abstract][Full Text] [Related]
15. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
16. Comparison of humoral and cellular immune responses between ChAd-BNT heterologous vaccination and BNT-BNT homologous vaccination following the third BNT dose: A prospective cohort study.
Sim W; Kang H; Jung J; Lee J; Ko GY; Park HS; Choi J; Park K; Oh EJ
Front Immunol; 2023; 14():1120556. PubMed ID: 36936965
[TBL] [Abstract][Full Text] [Related]
17. IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers.
Decru B; Van Elslande J; Steels S; Van Pottelbergh G; Godderis L; Van Holm B; Bossuyt X; Van Weyenbergh J; Maes P; Vermeersch P
Front Immunol; 2022; 13():909910. PubMed ID: 35784321
[TBL] [Abstract][Full Text] [Related]
18. Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children.
Gulmez R; Ozbey D; Agbas A; Aksu B; Yildiz N; Uckardes D; Saygili S; Yilmaz EK; Yildirim ZY; Tasdemir M; Kiykim A; Cokugras H; Canpolat N; Nayir A; Kocazeybek B; Caliskan S
Pediatr Nephrol; 2023 Jul; 38(7):2199-2208. PubMed ID: 36459243
[TBL] [Abstract][Full Text] [Related]
19. Interferon-gamma release assays outcomes in healthy subjects following BNT162b2 mRNA COVID-19 vaccination.
Kurteva E; Vasilev G; Tumangelova-Yuzeir K; Ivanova I; Ivanova-Todorova E; Velikova T; Kyurkchiev D
Rheumatol Int; 2022 Mar; 42(3):449-456. PubMed ID: 35059799
[TBL] [Abstract][Full Text] [Related]
20. 25-Hydroxyvitamin D concentrations do not affect the humoral or cellular immune response following SARS-CoV-2 mRNA vaccinations.
Lavell AHA; Schramade AE; Sikkens JJ; van der Straten K; van Dort KA; Slim MA; Appelman B; van Vught LA; Vlaar APJ; Kootstra NA; van Gils MJ; Smulders YM; de Jongh RT; Bomers MK;
Vaccine; 2024 Mar; 42(7):1478-1486. PubMed ID: 37775466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
